TD Private Client Wealth LLC Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

TD Private Client Wealth LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 29.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,217 shares of the company’s stock after selling 3,423 shares during the period. TD Private Client Wealth LLC’s holdings in Zoetis were worth $1,339,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Dunhill Financial LLC grew its position in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Atlantic Edge Private Wealth Management LLC grew its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares during the period. Quarry LP lifted its holdings in shares of Zoetis by 45.9% during the third quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after purchasing an additional 96 shares during the period. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis during the fourth quarter worth $58,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on ZTS. Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Zoetis Price Performance

Zoetis stock opened at $162.86 on Friday. The company has a market cap of $72.93 billion, a P/E ratio of 29.77, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The business has a fifty day moving average of $166.76 and a two-hundred day moving average of $175.47.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.